⁶⁸Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.

ABSTRACT: Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography (⁶⁸Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on ⁶⁸Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with ¹⁸F-sodium fluoride PET/CT and magnetic resonance imaging as well a

SUBMITTER: Petersen LJ 

PROVIDER: S-EPMC5492698 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature